Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapies for Visceral Leishmaniasis
NCT00696969Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Jun 2008
- Primary completion
- Jan 2010
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of amphotericin b, miltefosine, paromomycin in visceral leishmaniasis (VL), sponsored by Drugs for Neglected Diseases initiative. Started Jun 2008; status: completed.
02
Drugs
amphotericin bmiltefosineparomomycin
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT00696969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00696969.